Pathstone Holdings
VRTX icon

Pathstone Holdings’s Vertex Pharmaceuticals VRTX Stock Holding History

Pathstone Holdings’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.9M Buy
45,952
+1,690
+4% +$749K 0.07% 191
2026
Q1 		$19.8M Sell
44,262
-1,342
-3% -$626K 0.08% 187
2025
Q4 		$20.7M Buy
45,604
+7,725
+20% +$3.33M 0.08% 175
2025
Q3 		$14.8M Buy
37,879
+1,446
+4% +$604K 0.06% 230
2025
Q2 		$16.2M Sell
36,433
-1,441
-4% -$664K 0.06% 205
2025
Q1 		$18.4M Buy
37,874
+521
+1% +$243K 0.08% 187
2024
Q4 		$15M Sell
37,353
-3,300
-8% -$1.53M 0.07% 202
2024
Q3 		$18.9M Buy
40,653
+2,112
+5% +$1.01M 0.08% 174
2024
Q2 		$18.1M Buy
38,541
+1,538
+4% +$668K 0.08% 172
2024
Q1 		$15.5M Buy
37,003
+4,472
+14% +$1.89M 0.07% 197
2023
Q4 		$13.2M Buy
+32,531
New +$12M 0.07% 209

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Pathstone Holdings's VRTX Position: Q2 2026 in Review

Pathstone Holdings increased its Vertex Pharmaceuticals (VRTX) stake by 3.8% in Q2 2026, buying an estimated $749K and bringing the position to 45,952 shares worth $22.9M. The position accounts for 0.07% of the portfolio, ranked #191.

Pathstone Holdings first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Pathstone Holdings held 45,952 shares of Vertex Pharmaceuticals worth $22.9M as of Q2 2026.
  • Pathstone Holdings bought 1,690 Vertex Pharmaceuticals shares in Q2 2026, an estimated $749K.
  • Vertex Pharmaceuticals made up 0.07% of Pathstone Holdings's portfolio in Q2 2026, its #191 holding.
  • Pathstone Holdings first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.